We are thrilled to announce a collaboration between Pharmacelera and the UMass Chan Medical School aimed to support early-stage drug discovery projects.
Through this collaboration, Pharmacelera will use its cutting-edge computational chemistry technology, AI-driven molecular modelling platforms and industry-based expertise in medicinal chemistry to support several early-stage drug discovery programs targeting different families of targets with the aim of enhancing hit identification, lead optimization, and chemical space exploration.
“This partnership reflects our shared commitment to advancing science and bringing impactful therapeutics closer to the clinic,” said Enric Gibert, CEO of Pharmacelera. “Our technology is designed to push the frontiers of early drug discovery, and we are proud to support UMass Chan’s world-class research teams.”
“We are excited to partner with Pharmacelera to integrate their advanced modelling tools into our drug discovery workflows,” said Huseyin Mehmet, Executive Director, New Ventures, BRIDGE Innovation & Business Development of the UMass Chan Medical School. “This collaboration will enhance our ability to discover and optimize novel compounds for unmet medical needs in the areas of cancer and ALS.”
Stay tuned as we share more about our joint projects and scientific milestones in the coming months.
—
About UMass Chan Medical School
UMass Chan Medical School, one of five campuses of the University of Massachusetts system, comprises the T.H. Chan School of Medicine, the Morningside Graduate School of Biomedical Sciences, the Tan Chingfen Graduate School of Nursing, ForHealth Consulting at UMass Chan Medical School, MassBiologics, and a thriving Nobel-Prize-winning biomedical research enterprise. UMass Chan is advancing together to improve the health and wellness of our diverse communities throughout Massachusetts and across the world by leading and innovating in education, research, health care delivery and public service. It is ranked among the best medical schools in the nation for primary care education and biomedical research by U.S. News & World Report. Learn more at www.umassmed.edu.
About Pharmacelera
Pharmacelera develops advanced computational tools for the discovery of novel hits using accurate Quantum-Mechanics (QM), Artificial Intelligence (AI) and High-Performance Computing (HPC). The company’s products PharmScreen®, exaScreen® and PharmQSAR use 3D molecular descriptors derived from Quantum-Mechanics (QM) calculations to mine an unexplored chemical space and to identify hits uncovered by traditional algorithms. Pharmacelera is a private company founded in 2015 and based in Barcelona, Spain. The company works with several big pharma and biotech organizations across Europe and the United States.